Mysa Saad: Antiplatelets Increase Bleeding Without Reducing VTE in Cancer Patients
Mysa Saad, Internal Medicine Resident shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Our new study published in Thrombosis Research:
In ambulatory patients with cancer on apixaban thromboprophylaxis:
- Concurrent antiplatelet/NSAID use increases clinically relevant bleeding (HR 1.80)
- Antiplatelets were the main driver of increased bleeding risk (HR 2.02)
- NSAIDs did not have a significant impact on bleeding risk
- No significant reduction in VTE
These results highlight the need to carefully reassess indications for concurrent antiplatelet agents/NSAIDs when considering apixaban thromboprophylaxis in patients with cancer.”
Title: Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial
Authors: Mysa Saad, Tzu-Fei Wang, Ranjeeta Mallick, Danny Hill, Alejandro Lazo-Langner, Vicky Tagalakis, Philip S. Wells, Marc Carrier
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 16, 2026, 04:11Paolo Zamboni: Enjoy the New Super Articles From Veins and Lymphatics Page Press
-
Apr 16, 2026, 04:03Platelet DGD – A Common But Underdiagnosed Bleeding Disorder – RPTH
-
Apr 16, 2026, 03:51William Wallace: How Vitamin B12 Is Being Absorbed?
-
Apr 16, 2026, 03:36Santagata Davide: Atypical Vascular Events Revealing Underlying Clonal Autoinflammation
-
Apr 16, 2026, 03:35Iron Deficiency in Women During Reproductive Years – ASH
-
Apr 16, 2026, 03:33Abdallah Othman: Overview of Coronary Arterial Anatomy and Its Clinical Implications
-
Apr 16, 2026, 03:14Laura Girardi: A Survey Study on the Management of Incidental Pulmonary Embolism in Patients with Cancer
-
Apr 16, 2026, 03:10Folusho Adeosun: Your 30-Minute Plan for SCD Emergencies
-
Apr 16, 2026, 02:57Charlie Windri: CAC as the Missing Link in Lp(a) Risk